PB
CRSP icon

Pinnacle Bancorp’s CRISPR Therapeutics CRSP Stock Holding History

Pinnacle Bancorp’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.69K Hold
86
– – ﹤0.01% 843
2026
Q1 		$4.09K Hold
86
– – ﹤0.01% 822
2025
Q4 		$4.51K Hold
86
– – ﹤0.01% 796
2025
Q3 		$5.57K Hold
86
– – ﹤0.01% 801
2025
Q2 		$4.18K Hold
86
– – ﹤0.01% 814
2025
Q1 		$2.93K Hold
86
– – ﹤0.01% 829
2024
Q4 		$3.38K Hold
86
– – ﹤0.01% 825
2024
Q3 		$4.04K Hold
86
– – ﹤0.01% 805
2024
Q2 		$4.64K Hold
86
– – ﹤0.01% 767
2024
Q1 		$5.86K Hold
86
– – ﹤0.01% 723
2023
Q4 		$5.38K Hold
86
– – ﹤0.01% 703
2023
Q3 		$3.9K Hold
86
– – ﹤0.01% 719
2023
Q2 		$4.83K Hold
86
– – ﹤0.01% 686
2023
Q1 		$3.89K Buy
+86
New +$4.18K ﹤0.01% 723

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pinnacle Bancorp's CRSP Position: Q2 2026 in Review

Pinnacle Bancorp held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 86 shares worth $4.69K. The position accounts for ﹤0.01% of the portfolio, ranked #843.

Pinnacle Bancorp first reported a position in CRSP in Q1 2023 and has held it in 14 quarters since. The position peaked at $5.86K in Q1 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Pinnacle Bancorp held 86 shares of CRISPR Therapeutics worth $4.69K as of Q2 2026.
  • Pinnacle Bancorp left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Pinnacle Bancorp's portfolio in Q2 2026, its #843 holding.
  • Pinnacle Bancorp first reported a position in CRISPR Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Pinnacle Bancorp's CRISPR Therapeutics position peaked at $5.86K in Q1 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Pinnacle Bancorp's 13F filing for Q2 2026, filed 28 Jul 2026.